Dr. Filippo Mulinacci currently serves as Chief Business Officer at Araris Biotech AG, a cutting-edge biotech company pioneering novel antibody-drug conjugate (ADC) linker technology.

He holds a Master’s degree in Chemistry from Università degli Studi di Torino, a Ph.D. in Pharmaceutical Sciences from University of Geneva, and an MBA in General Management from University of St. Gallen.

With over two decades of experience across both scientific research and business development, Filippo began his career in pharmaceutical research at Serono SA, then transitioned into licensing and business development — taking on roles at F. Hoffmann-La Roche AG, Philogen S.p.A., and Basilea Pharmaceutica.

At Araris Biotech, he leads global business development, strategic partnerships, licensing, and alliance management, helping to bring next-generation oncology therapeutics toward clinical application.